<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172129</url>
  </required_header>
  <id_info>
    <org_study_id>R11014-3-D</org_study_id>
    <nct_id>NCT04172129</nct_id>
  </id_info>
  <brief_title>Assessment of Implant Fixation and SF-36 for Short Hip-Stems - A Prospective Clinical Study</brief_title>
  <official_title>Assessment of Implant Fixation and SF-36 for Short Hip-Stems - A Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew Orthopaedics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study was to evaluate the implant fixation of the NANOS™ Neck&#xD;
      Preserving Hip Stem (OHST Medizintechnik AG, distributed by Smith &amp; Nephew GmbH, Marl,&#xD;
      Germany) by measuring the migration of the implant using the model-based roentgen&#xD;
      stereophotogrammetric analysis (MBRSA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2011</start_date>
  <completion_date type="Actual">February 15, 2017</completion_date>
  <primary_completion_date type="Actual">January 4, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of migration pattern of the Nanos stem</measure>
    <time_frame>2 years</time_frame>
    <description>Measuring migration used the model-based RSA method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Measuring change in quality of life using the Short Form (SF) 36 Mental Component Score&#xD;
Minimum Value: 0 (worst outcome)&#xD;
Maximum Value: 100 (best outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Score</measure>
    <time_frame>2 years</time_frame>
    <description>Investigator assessed outcome score Minimum: 0 (worst outcome) Maximum: 100 (best outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of California, Los Angeles (UCLA) scale</measure>
    <time_frame>2 years</time_frame>
    <description>Score rating the patient's current activity level&#xD;
Minimum: 1 (wholly inactive subject)&#xD;
Maximum: 10 (totally active subject)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Visual Analogue Scale</measure>
    <time_frame>2 years</time_frame>
    <description>Score representing patient's current pain intensity&#xD;
Minimum: 0 (no pain)&#xD;
Maximum: 100 (very severe pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postel Merle d'Aubigné-Score</measure>
    <time_frame>2 years</time_frame>
    <description>Score grading the functional value of the hip&#xD;
Minimum: 0 (worst outcome)&#xD;
Maximum: 6 ( best outcome)&#xD;
Grading is done in each of the three dimensions: pain, mobility and ability to walk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip Disability and Ostheoarthritis Outcome Score</measure>
    <time_frame>2 years</time_frame>
    <description>Patient reported outcome&#xD;
Minimum: 0 (best outcome)&#xD;
Maximum: 96 (worst outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Evaluation</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of radiographic images regarding implant position, implant fixation, heterotopic ossifications (HO), radiolucencies, osteolysis, atrophy and hypertrophy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Collection of adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Primary and Secondary Coxarthrosis</condition>
  <condition>Dysplasia Coxarthrosis</condition>
  <condition>Post-traumatic Necrosis of the Femoral Head</condition>
  <arm_group>
    <arm_group_label>NANOS</arm_group_label>
    <description>NANOS™ Neck Preserving Hip Stem</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total Hip Arthroplasty</intervention_name>
    <arm_group_label>NANOS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients identified in the primary care clinic with need for total hip arthroplasty&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject required primary total hip arthroplasty unilateral or bilateral with a&#xD;
             diagnosis of primary and secondary coxarthrosis, dysplasia coxarthrosis and&#xD;
             post-traumatic necrosis of the femoral head confirmed by x-ray analysis. For bilateral&#xD;
             subjects at least three months between surgical procedures were required.&#xD;
&#xD;
          -  Subject was willing to consent to participate in the study and planned to be available&#xD;
             for the follow-up examinations.&#xD;
&#xD;
          -  Subject had normal motor function of the lower extremities, documented through&#xD;
             clinical examinations and lack of signs of a neurological disease with changed motor&#xD;
             function.&#xD;
&#xD;
          -  Subject was 30 to 65 (inclusive) years of age at time of surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject had previous bone or soft tissue surgery of the affected hip except for&#xD;
             arthroscopic surgery.&#xD;
&#xD;
          -  Subject had a local or systemic infection.&#xD;
&#xD;
          -  Subject had previously diagnosed osteoporosis.&#xD;
&#xD;
          -  Subject had a femoral neck angle of &gt;145°.&#xD;
&#xD;
          -  Subject had a femoral neck angle of &lt;125°.&#xD;
&#xD;
          -  Subject had a disease of the cardiovascular system involving particularly reduced load&#xD;
             capacity in the everyday life, counting as contraindication of physical stress&#xD;
             (American Society of Anaesthesiologists' (ASA) Score 3 or 4).&#xD;
&#xD;
          -  Subject had a documented allergy against elements of the implanted device.&#xD;
&#xD;
          -  Subject had a neurological disease with changed motor function.&#xD;
&#xD;
          -  Subject was pregnant.&#xD;
&#xD;
          -  Subject had a Body Mass Index (BMI) &gt; 30.&#xD;
&#xD;
          -  Subject suffered from alcoholism or addictive disorders.&#xD;
&#xD;
          -  Subject needed a revision hip arthroplasty.&#xD;
&#xD;
          -  Subject had an insufficient command of the language to understand patient information&#xD;
             and consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Windhagen, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopädische Klinik der Medizinischen Hochschule Hannover</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orthopädische Klinik der Medizinischen Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nanos</keyword>
  <keyword>THA</keyword>
  <keyword>MBRSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Hip</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

